300 related articles for article (PubMed ID: 9215597)
1. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
2. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Wachtel H; Kunow M; Löschmann PA
Neurosci Lett; 1992 Aug; 142(2):179-82. PubMed ID: 1280793
[TBL] [Abstract][Full Text] [Related]
3. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Löschmann PA; Kunow M; Wachtel H
J Neural Transm Suppl; 1992; 38():55-64. PubMed ID: 1491248
[TBL] [Abstract][Full Text] [Related]
4. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
6. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
7. Intra-nigra infusion of AMPA attenuates dopamine-dependent rotation in the rat.
Burns LH; Sato K; Wüllner U; Isacson O
Neuroreport; 1993 Sep; 4(9):1075-8. PubMed ID: 7693018
[TBL] [Abstract][Full Text] [Related]
8. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
9. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
[TBL] [Abstract][Full Text] [Related]
10. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors.
Christoffersen CL; Meltzer LT
Neuroscience; 1995 Jul; 67(2):373-81. PubMed ID: 7545793
[TBL] [Abstract][Full Text] [Related]
11. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
Klockgether T; Turski L; Honoré T; Zhang ZM; Gash DM; Kurlan R; Greenamyre JT
Ann Neurol; 1991 Nov; 30(5):717-23. PubMed ID: 1662477
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
Morelli M; Fenu S; Pinna A; Di Chiara G
J Pharmacol Exp Ther; 1992 Jan; 260(1):402-8. PubMed ID: 1346165
[TBL] [Abstract][Full Text] [Related]
13. Systemic excitatory amino acid receptor antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and of the N-methyl-D-aspartate (NMDA) receptor relieve mechanical hypersensitivity after transient spinal cord ischemia in rats.
Xu XJ; Hao JX; Seiger A; Wiesenfeld-Hallin Z
J Pharmacol Exp Ther; 1993 Oct; 267(1):140-4. PubMed ID: 8229741
[TBL] [Abstract][Full Text] [Related]
14. Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra.
Fenu S; Carta A; Morelli M
Synapse; 1995 Apr; 19(4):233-40. PubMed ID: 7792718
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice.
Starr MS; Starr BS
Psychopharmacology (Berl); 1994 Apr; 114(3):469-76. PubMed ID: 7855205
[TBL] [Abstract][Full Text] [Related]
16. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
18. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity.
Paul ML; Currie RW; Robertson HA
Neuroscience; 1995 May; 66(2):347-59. PubMed ID: 7477877
[TBL] [Abstract][Full Text] [Related]
19. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
20. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
